Introduction {#Sec1}
============

Colorectal cancer (CRC) is the second leading cause of cancer mortality worldwide and the third most frequently diagnosed malignancy (Cassidy and Syed [@CR8]). The CRC incidence and mortality rates have declined in recent decades, largely attributed to the contribution of preventive screening and early detection (Siegel et al. [@CR42]). However, rapid increases in prevalence have been noted in previously low-risk countries, such as China, and have been ascribed to particular increases in the prevalence of obesity and physical inactivity (Varghese and Shin [@CR45]). CRC places a financial and economic burden worldwide, especially in developing countries (Alefan et al. [@CR2]). Thus, effective therapies for CRC are needed urgently. To achieve this goal, it is important to explore the genetic and molecular abnormalities underlying CRC.

B-cell translocation gene 3 (BTG3) belongs to the B-cell translocation gene (BTG)/transducer of the ErbB2 family, which comprises structurally related proteins that appear to have antiproliferative properties (Winkler [@CR47]). BTG3 is reportedly a candidate tumor suppressor, as it inhibits cell proliferation and migration, and regulates cell cycle progression in several tumors, such as gastric cancer (Ren et al. [@CR39]) and esophageal adenocarcinoma (Gou et al. [@CR17]; Du et al. [@CR15]). Previous studies have demonstrated that BTG3 expression is downregulated in many cancers, including prostate cancer, renal carcinoma, and hepatocellular carcinoma (Majid et al. [@CR33], [@CR32]; Lv et al. [@CR31]). Moreover, BTG3 expression may predict survival and prognosis in patients with gastric cancer and ovarian carcinoma (Ren et al. [@CR39]; Deng et al. [@CR13]). However, BTG3 status in patients with CRC and its causal role in the development of CRC remain elusive.

To clarify the biological functions of BTG3 in CRC, we first explored the expression of BTG3 in CRC clinical samples and investigated its clinicopathological features and prognostic value. Then, we evaluated the effects of depleting BTG3 on cell proliferation, the cell cycle distribution, apoptosis, migration, and invasion of CRC cells. Finally, a microarray analysis revealed that multiple pathways critical for CRC development and progression were regulated and the expression of several signaling related genes was altered by BTG3 knockdown, providing valuable insight into the molecular mechanisms underlying BTG3-mediated biological functions in CRC.

Materials and methods {#Sec2}
=====================

Colon cancer clinical tissue specimens and cell culture {#Sec3}
-------------------------------------------------------

A total of 140 cases of paraffin specimens of primary colon cancer were obtained by surgical resection from the Department of Pathology, Shengjing Hospital affiliated with China Medical University from 2013 to 2014. Patients were not pretreated with radiotherapy or chemotherapy prior to surgery. The patients were followed up, and their complete clinical data were collected. Overall survival (OS) was defined as the interval between the dates of surgery and death. Disease-free survival (DFS) was defined as the interval between the dates of surgery and disease recurrence; if disease recurrence was not diagnosed, patients were censored at the date of death or last follow-up.

Histological types were assigned according to the criteria of the National Comprehensive Cancer Network classification system. Matched adjacent normal colorectal tissues from the macroscopic tumor margin (at least more than 5 cm away from the tumor and histologically confirmed) were isolated at the same time and used as the control. This study was approved by the Ethics Committee of the Affiliated Shengjing Hospital of China Medical University. The ethics number was 2016PS274K. Informed consent was obtained from all patients prior to tissue acquisition.

The HT29, HCT116, SW480, SW620, LoVo, and RKO CRC cell lines were obtained from Cell Bank of Chinese Academy of Sciences (Shanghai, China). They were cultured in RPMI 1640, DMEM, or Ham's F12K medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin (Hyclone) and maintained in an incubator with a humidified atmosphere of 95% air and 5% CO~2~ at 37 °C.

Immunohistochemistry {#Sec4}
--------------------

An immunohistochemical analysis was performed on 4-mm, formalin-fixed, paraffin-embedded tissue sections according to the following procedures. Briefly, consecutive sections were deparaffinized in xylene, rehydrated in a graded ethanol series, and submerged in EDTA antigenic retrieval buffer for 15 min in a microwave oven. The sections were treated with 3% hydrogen peroxide in absolute methanol for 20 min to block endogenous peroxidase activity. 5% bovine serum albumin was applied for 15 min to prevent non-specific binding. The sections were incubated with a rabbit polyclonal antibody against human BTG3 (1:100; Abcam, Cambridge, MA, USA) overnight at 4 ℃. After the incubation with secondary antibody, the visualization signal was developed with 3,3′-diaminobenzidine tetrachloride. The primary antibody was omitted for the negative control.

BTG3 immunostaining densities were quantitatively assessed with NIS-Elements BR 3.0 (Nikon, Tokyo, Japan). In brief, the sections were placed on a microscope (Nikon E800), and the images were transferred from a digital camera (Nikon 80i) to a computer. Three visual fields were randomly inspected on all slides under high-power magnification. The mean optical density (MOD) of the positive areas was measured. The results are expressed as the exact value of the relative optical density units.

Recombinant lentiviral vector construction and cell infection {#Sec5}
-------------------------------------------------------------

shRNA specifically targeting the BTG3 gene (NM_001130914.1) was designed and the lentivirus was constructed and prepared to deplete BTG3. Briefly, shRNA1 (target sequence: AGGAATGTATCGAGGGAAT) and shRNA2 (target sequence: TGAGAAATTGACCCTAATA) targeting human BTG3 were designed and the negative control sequence was as follows: TTCTCCGAACGTGTCACGT. Related stem-loop DNA oligonucleotides were synthesized, annealed, and inserted into lentiviral vector pGCSIL-GFP (GeneChem, Shanghai, China). The Lentivector Expression System (GeneChem) was used to produce lentivirus expressing BTG3 shRNA or the silencing negative control sequence shRNA.

Infection of CRC cells with lentivirus {#Sec6}
--------------------------------------

HCT116 and LoVo cells were plated in 12-well plates and infected with a lentivirus expressing BTG3 (shRNA1 and shRNA2) or the silencing negative control sequence shRNA was added according to the multiplicity of infection. After 72 h of infection, the cells were observed under a fluorescence microscope (MicroPublisher 3.3RTV; Olympus). After 120 h of infection, the cells were harvested to determine knockdown efficiency by western blot analysis.

Western blot analysis {#Sec7}
---------------------

The cells were collected and lysed using ice-cold lysis buffer containing 1 mM protein inhibitor and 1 mM PMSF for 30 min on ice. The cell lysates were centrifuged at 12,000×*g* at 4 °C for 30 min, and the supernatants were collected. After the protein was quantified by Coomassie Brilliant Blue staining, 40 mg of protein was loaded in a loading buffer, resolved by 10% SDS-polyacrylamide gel electrophoresis, electrotransferred to PVDF membranes, and incubated overnight with primary antibody (STAT3, FOS, RPS6KA5, RAP1A, DUSP6, ATF4 from Abcam; STAT1, PAK2, YWHAB from CST; GAPDH from Santa Cruz Biotechnology, Santa Cruz, CA, USA; β-actin from ZSBIO, Beijing, China). Secondary antibody was applied, and the relative content of the target proteins was detected with an enhanced chemiluminescence reagent (SuperSignal West Pico; ThermoScientific, Rockford, IL, USA). β-actin was used as the loading control.

Cell proliferation assay {#Sec8}
------------------------

About 2 × 10^3^ cells/wells were seeded on a 96-well plate. The Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) was employed to determine the number of viable cells over 5 days. In brief, 10 μL of CCK-8 solution was added to each well of the plate at different time points, and the plates were incubated for 4 h in an incubator and absorbance was measured at 450 nm. Each cell group was plated in three duplicate wells.

Cell cycle analysis {#Sec9}
-------------------

About 1 × 10^6^ cells were trypsinized, washed twice with PBS, and fixed in cold 10 mL of ethanol overnight. Then, the cells were centrifuged to remove the ethanol, washed twice in PBS, and incubated with 100 μL RNase at 37 °C for 30 min. The cells were pelleted and resuspended in 400 μL propidium iodide and incubated at 4 °C in the dark for 30 min. Finally, flow cytometry was employed to examine the cell cycle distribution.

In vitro apoptosis assay {#Sec10}
------------------------

About 2 × 10^5^ cells were harvested and stained with 7-AAD and FITC-labeled Annexin V (KGA1017; KeyGEN Biotech, Nanjing, China,) to detect phosphatidylserine externalization as an endpoint indicator of apoptosis according to the manufacturer's instructions by flow cytometry using a BD FACSCalibur system (Becton Dickinson, Brea, CA, USA).

Transwell chamber assays {#Sec11}
------------------------

About 8 × 10^4^ cells were resuspended in serum-free RPMI 1640 and seeded in the upper chamber (3422; Corning COSTAR, Corning, NY, USA) with Corning Matrigel (cat \# 356243). The lower compartment of the chamber was filled with RPMI-1640 and 10% FBS as a chemoattractant. After a 37 °C incubation in 5% CO~2~ for 24 h, the cells on the membrane were scrubbed, washed with PBS, fixed in 100% methanol, and stained with Crystal Violet Staining Solution (Solarbio, Beijing, China) for 30 min. The procedures for the migration assay were the same as described above, except no Matrigel was used. The cells in the lower chamber were counted under a light microscope in five random visual fields (×200).

Microarray processing and analysis {#Sec12}
----------------------------------

Total RNA from HCT116 cells infected with lentivirus expressing either NC/shRNA (*n* = 3) or BTG3/shRNA1 (*n* = 3) was extracted using Trizol reagent. Then, RNA quantity and quality were assessed with the Thermo NanoDrop 2000 and Agilent 2100 Bioanalyzer. Affymetrix human GeneChip primeview was used for microarray processing to determine the gene expression profile according to the manufacturer's instructions (Affymetrix Inc., San Diego, CA, USA). In brief, reverse transcription, double-stranded DNA template transformation, in vitro transcription for mRNA synthesis, and biotin labeling were all conducted using the GeneChip 3′ IVT Expression Kit. Microarray hybridization, washing, and staining were performed using the GeneChip Hybridization Wash and Stain Kit. The arrays were scanned using the GeneChip Scanner 3000 to produce raw data. Significant differentially expressed genes between HCT116 cells treated with BTG3/shRNAs and HCT116 cells treated with NC/shRNAs were selected based on the following criteria: *p* value \< 0.05 and absolute fold change \> 1.3.

IPA {#Sec13}
---

All of the significantly differentially expressed genes were used to query the Ingenuity Pathway Analysis (IPA) system (Ingenuity Systems, Mountain View, CA, USA) and to compose a set of interactive networks considering canonical pathways, relevant biological interactions, cellular and disease processes, and molecular regulatory networks.

Statistical analysis {#Sec14}
--------------------

The SPSS 23.0 statistical package was used (SPSS Inc. Chicago, IL, USA). Means were compared using Student's *t* test or analysis of variance. Univariate analyses were performed using the Kaplan--Meier method and comparisons between survival curves were made with log-rank statistics. Cox multivariate analysis was used to determine the independent prognostic factors. The "minimum *p* value" approach (Wolfgang [@CR48]; Budczies et al. [@CR7]) was used to obtain the optimal cutoff value for the best separation between groups of patients in relation to OS or DFS. A two-tailed P value \< 0.05 was considered significant.

Results {#Sec15}
=======

BTG3 is downregulated in human CRC tissues and correlated with clinicopathological parameters and prognosis {#Sec16}
-----------------------------------------------------------------------------------------------------------

Immunohistochemical staining (IHC) was performed in 140 paired paraffin-embedded samples to detect the expression of BTG3 and its clinicopathological characteristics in patients with CRC. Compared to the relatively stronger cytoplasmic expressions of BTG3 in adjacent normal colorectal tissues (Fig. [1](#Fig1){ref-type="fig"}a), BTG3 expressed in tumor tissues with mostly moderate to weak cytoplasmic staining (Fig. [1](#Fig1){ref-type="fig"}b, c). More important, the majority of adenocarcinoma tissues showed significantly higher cytoplasmic expression of BTG3 than mucinous adenocarcinoma (Fig. [1](#Fig1){ref-type="fig"}c). Consistent with these findings, the mean optical density of BTG3 expression in CRC tissues was significantly lower than that in adjacent normal tissue (*p* \< 0.0001, Fig. [1](#Fig1){ref-type="fig"}d). Clinicopathological analyses showed that BTG3 expression was correlated with pathological classification (*p* = 0.037), depth of invasion (*p* = 0.016), distant metastasis (*p* = 0.024), and TNM stage (*p* = 0.007, Table [1](#Tab1){ref-type="table"}). A survival analysis was conducted to assess the prognostic value of BTG3 expression. Using the "minimum P value" approach, the mean optical density (MOD) values of 0.2285 and 0.2345 were the best cutoff values for overall survival (OS) and disease-free survival (DFS). Follow-up information was available on 140 patients with CRC for 2--45 months (median = 34 months). A Kaplan--Meier analysis revealed that patients with CRC and relatively high BTG3 expression had significantly longer OS and DFS rates than those with low BTG3 expression (OS rate, *p* = 0.0045, Fig. [1](#Fig1){ref-type="fig"}e; DFS rate, *p* = 0.0011, Fig. [1](#Fig1){ref-type="fig"}f). The significant prognostic factors for both OS and DFS rates in the univariate analysis were BTG3 expression (*p* = 0.007 and *p* = 0.002), lymphatic invasion (*p* = 0.019 and *p* = 0.024), and TNM stage (*p* = 0.022 and *p* = 0.030, Table [2](#Tab2){ref-type="table"}). Further analysis with a multivariate Cox proportional hazards model demonstrated that BTG3 expression (*p* = 0.005 and *p* = 0.016), together with lymphatic invasion (*p* = 0.041 and *p* = 0.047, Table [2](#Tab2){ref-type="table"}) were strongly associated with OS and DFS rates.

Fig. 1Expression of BTG3 in clinical paraffin-embedded CRC tissues and survival analysis of BTG3 expression in patients with CRC. **a** Strong positive expression of BTG3 in adjacent normal colorectal tissues (×400). **b** Moderate cytoplasmic BTG3 staining in adenocarcinoma tissues (×400). **c** Weak expression of BTG3 in mucinous adenocarcinoma tissues (×400). Arrows indicate the cytoplasmic BTG3 staining. **d** IHC analysis results of BTG3 expression in 140 patients with CRC. Mean optical density (MOD) values were significantly lower in CRC tissues than paired adjacent normal colorectal tissues (*p* \< 0.0001). **e** Kaplan--Meier survival analysis for overall survival rate of patients with high and low BTG3 expression (*p* = 0.0045). **f** Kaplan--Meier survival analysis for disease-free survival rate of patients with high and low BTG3 expression (*p* = 0.0011)

Table 1The relationship between BTG3 expression and clinicopathological features of colon carcinomasVariablesTotal numberBTG3 expressionMODSD*p* valueGender0.599 Male780.2700.056 Female620.2640.061Age (years)0.649 \< 62700.2690.055 ≥ 62700.2650.061Tumor location0.991 Right sided930.2670.056 Transverse sided60.2680.070 Left sided410.2680.063Pathological classification0.037\* Well/moderately differentiated adenocarcinoma1180.2710.060 Poorly differentiated/mucinous adenocarcinoma220.2470.044Depth of invasion0.016\* T1-2100.3000.037 T3-41300.2650.059Lymphatic invasion0.101 Negative820.2740.055 Positive580.2580.062Distant metastasis0.024\* MO1350.2690.058 M150.2100.030TNM staging0.007\* I60.3180.014 II750.2710.055 III550.2610.061 IV40.2030.029Vascular invasion No1180.2690.0590.448 Yes220.2590.053Nerve invasion No1090.2680.0560.718 Yes310.2640.066*SD* standard deviation, *MOD* mean optical density\**p* \< 0.05

Table 2Univariate and multivariate analyses of individual parameters for correlation with OS or DFS rateVariablesOS*p* valueDFS*p* valueRelative risk (95% CI)Relative risk (95% CI)Univariate analysis BTG3 MOD  (\> 0.2285 *vs* \< 0.2285) for OS0.338 (0.154--0.741)0.007\*  (≥ 0.2345 *vs* \< 0.2345) for DFS0.305 (0.143--0.651)0.002\* Differentiation (poorly vs well/moderate)1.094 (0.375--3.187)0.8700.995 (0.345--2.870)0.993 Pathological classification (mucinous vs tubular)1.827 (0.625--5.337)0.2711.558 (0.540--4.493)0.412 Depth of invasion (T3-4 vs T1-2)1.748 (0.236--12.945)0.5840.969 (0.230--4.088)0.965 Lymphatic invasion (positive vs negative)2.667 (1.178--6.037)0.019\*2.398 (1.123--5.121)0.024\* Distant metastasis (positive vs negative)1.043 (0.141--7.714)0.9670.962 (0.131--7.080)0.970 TNM staging (III/IV vs I/II)2.600 (1.149--5.884)0.022\*2.321 (1.087--4.956)0.030\* Vascular invasion (positive vs negative)1.166 (0.400-3.401)0.7790.961 (0.333--2.771)0.942 Nerve invasion (positive vs negative)1.167 (0.466--2.923)0.7420.980 (0.397--2.418)0.966Multivariate analysis BTG3 MOD0.378 (0.171--0.837)0.016\*  (≥ 0.2285 vs \< 0.2285) for OS  (≥ 0.2345 vs \< 0.2345) for DFS0.331 (0.154--0.710)0.005\* Differentiation (poorly vs well/moderate)NANA Pathological classification (mucinous vs tubular)NANA Depth of invasion (T3-4 vs T1-2)NANA Lymphatic invasion (positive vs negative)2.362 (1.035--5.39)0.041\*2.131 (0.992--4.574)0.047\* Distant metastasis (positive vs negative)NANA TNM staging (III/IV vs I/II)NANA Vascular invasion (positive vs negative)NANA Nerve invasion (positive vs negative)NANA*OS* overall survival, *DFS* disease-free survival, *95% CI* 95% confidence interval, *MOD* mean optical density, *NA* not applicable\**p* \< 0.05

Loss of BTG3 promotes proliferation in the G2 phase, inhibits apoptosis, and promotes migration and invasion of CRC cell lines {#Sec17}
------------------------------------------------------------------------------------------------------------------------------

To investigate the causative effects of BTG3 in the carcinogenesis of CRC, we first examined endogenous protein expression of BTG3 in HT29, HCT116, SW480, SW620, LoVo, and RKO cells by western blotting. HCT116 and LoVo cells exhibit relatively high expression of BTG3 (Fig. [2](#Fig2){ref-type="fig"}a) and were chosen for constructing the lentiviral-mediated small hairpin RNA (shRNA) cell lines. Cells were infected with lentivirus expressing BTG3/shRNA1 and shRNA2 or a silencing negative control sequence (NC/shRNA). The western blot results showed that BTG3/shRNA1 inhibited BTG3 expression with higher knockdown efficiency in the two cell lines (Fig. [2](#Fig2){ref-type="fig"}b). The CCK8 assay showed that the fold changes in OD450 values with BTG3/shRNA increased significantly in a time-dependent manner, compared with the control group. The promotive role of proliferation in the BTG3/shRNA1 group seemed more obvious than that in the BTG3/shRNA2 group (Fig. [2](#Fig2){ref-type="fig"}c). The deregulated cell cycle in tumors permits sustaining cell proliferation. Flow cytometry was conducted to further validate whether the promotive effect of BTG3 knockdown on CRC cell proliferation was mediated by a specific stage of the cell cycle. The results revealed that the BTG3/shRNA groups in both HCT116 and LoVo cells showed a significant decrease in the percentage of cells in the G2 peak compared with the NC group (BTG3/shRNA1 *p* \< 0.01; BTG3/shRNA2 *p* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}d). These results suggest that BTG3 knockdown promoted CRC cell proliferation by relieving G2 phase arrest. Next, we determined the effect of BTG3 knockdown on apoptosis with Annexin V-PE/7AAD and flow cytometry. Cells in the lower right quadrant represented late apoptotic cells (Annexin V-PE positive/7-AAD positive). The rate of late apoptotic BTG3-depleted cells decreased significantly compared to that of the control, especially in the BTG3/shRNA1 group, suggesting that BTG3 knockdown inhibited CRC cell apoptosis (Fig. [2](#Fig2){ref-type="fig"}e). The effect of BTG3 knockdown on migration and invasion of HCT116 and LoVo cells was explored in Transwell assays. Significantly more HCT116 and LoVo cells migrated and invaded in the BTG3/shRNA group than that in the control group and the increase in the BTG3/shRNA1 group was more significant than that in BTG3/shRNA2 group (Fig. [2](#Fig2){ref-type="fig"}f). These results suggest that loss of BTG3 promoted migration and invasion of the CRC cell lines.

Fig. 2The effects of BTG3 knockdown on the phenotypes in CRC cells. **a** Western blotting analysis of BTG3 expression in six cell lines. **b** Western blotting analysis of BTG3 expression in HCT116 and LoVo cells with BTG3 knockdown. **c** Promotive effect of BTG3 knockdown on cell proliferation in vitro by the CCK-8 assay. **d** BTG3 knockdown decreased the percentage of G2 phase cells in the cell cycle transition. **e** Inhibitory effect of BTG3 knockdown on cell apoptosis. **f** HCT116 cells and LoVo cells with BTG3 knockdown showed an enhanced ability to migrate and invade. \**p* \< 0.05, \*\**p* \< 0.01, compared with that in the BTG3/NC group

Interruption of multiple critical pathways involved in cancer development by BTG3 knockdown {#Sec18}
-------------------------------------------------------------------------------------------

The results revealed that decreased BTG3 expression is linked to carcinogenesis and aggressiveness of the CRC cell lines. However, the mechanisms underlying BTG3-mediated CRC development and its downstream pathways have not been systematically investigated. Here, genome-wide gene expression profiling of HCT116 cells infected with either BTG3/shRNA1 or NC/shRNA was analyzed using a microarray platform. In total, 554 genes were significantly differentially expressed (*p* \< 0.05 and absolute fold change \[FC absolute\] \> 1.3), among which 281 were upregulated and 273 were downregulated (Fig. [3](#Fig3){ref-type="fig"}a). Analysis of the microarray data using the Ingenuity Pathway Analysis (IPA) system showed several dysregulated cellular and molecular functions mediated by BTG3 knockdown, such as impaired cell death and survival, apoptosis, cellular growth and proliferation, cancer, cell cycle progression, and other disrupted cellular functions (Fig. [3](#Fig3){ref-type="fig"}b). The "canonical pathway" module was used to analyze the microarray data and to systematically explore the downstream pathways involved in cancer development, such as unfolded protein response signaling, endoplasmic reticulum stress signaling, and insulin-like growth factor-1 signaling (Fig. [3](#Fig3){ref-type="fig"}c). Among these impaired canonical pathways, extracellular-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling was highlighted. Furthermore, the IPA system listed several molecules involved in ERK/MAPK signaling mediated by BTG3 knockdown (Fig. [4](#Fig4){ref-type="fig"}a). Those differentially expressed genes were validated by western blot analysis in HCT116 cells and demonstrated that the PAK2, RPS6KA5, YWHAB, and signal transducer and activator of transcription (STAT)3 protein levels increased significantly, whereas those of RAP1A, DUSP6, and STAT1 clearly decreased in the BTG3/shRNA1 groups than those in the NC group. cFos and activating transcription factor 4 (ATF4) showed no conspicuous difference between the two groups (Fig. [4](#Fig4){ref-type="fig"}b). These results validated the gene expression profile results and are consistent with the microarray analysis.

Fig. 3Microarray analysis and Ingenuity Pathway Analysis (IPA) of HCT 116 cells with BTG3 knockdown. **a** Heatmap representation of genes that were significantly differentially expressed in BTG3 cells infected with lentivirus expressing either BTG3/shRNA or NC/shRNA. Genes and samples are listed in rows and columns, respectively. A color scale for the normalized expression data is shown at the bottom of the microarray heatmap (red represents upregulated genes and green represents downregulated genes). **b** The IPA system revealed several dysregulated cellular and molecular functions. Here, the top ten diseases and functions were sorted in descending order by the inverse log of the *p* value. **c** Histogram shows the enrichment of differentially expressed genes in the classical signaling pathways. Activated (orange) and inhibited (blue) canonical pathways based on IPA databases were sorted in descending order by the inverse log of the *p* value. **d** The schematic diagram showed several major roles of the extracellular-regulated kinase/mitogen-activated kinase (ERK/MAPK) signaling pathway

Fig. 4Western blotting validation of downstream genes indicated by the microarray and Ingenuity Pathway Analysis (IPA) data in HCT116 cell lines. **a** IPA shows several molecules involved in extracellular-regulated kinase/mitogen-activated kinase (ERK/MAPK) signaling changed in response to BTG3 knockdown. **b** The differential expression of molecules was screened by western blotting. **c** Representative histograms depicting validation of the involved proteins. \**p* \< 0.05, compared with the BTG3/negative control (NC) group

Discussion {#Sec19}
==========

Previous studies have indicated that BTG3 is a candidate tumor suppressor gene in various cancers (Lv et al. [@CR31]; Lin et al. [@CR30]; Majid et al. [@CR32]; Gou et al. [@CR17]). However, our knowledge of the expression patterns and function of BTG3 in the progression of CRC remains vague. In the present study, we first quantified BTG3 expression by comparing MOD values and found that BTG3 was significantly downregulated in CRC tissues compared with adjacent normal colorectal tissues, which indicated that downregulation of BTG3 may be associated with the progression of CRC. This result is consistent with other studies (Chen et al. [@CR9]; Yu et al. [@CR51]). Additionally, positively associations with BTG3 expression level and OS and DFS in patients with CRC and the multivariate analysis demonstrated that BTG3 expression was an independent factor indicating a favorable prognosis for CRC. A similar conclusion was reported in previous studies (Ren et al. [@CR39]; Deng et al. [@CR13]).

The positive correlation between BTG3 expression and clinicopathological characteristics suggested that BTG3 might be involved in CRC development and progression. To further clarify the roles of BTG3 in colorectal carcinogenesis and progression, we evaluated the effects of downregulating BTG3 on cell proliferation, the cell cycle, and apoptosis. Here, we observed that knockdown of BTG3 promoted CRC cell proliferation but inhibited CRC cell apoptosis. These results provide more support for an anticarcinogenic role in CRC and concur with those in hepatocellular carcinoma and gastric cancers (Lv et al. [@CR31]; Ren et al. [@CR39]). BTG3 dysregulates the S-phase by interacting with E2F1 to suppress binding of the E2F1-DP1 complex (Ou et al. [@CR37]). As a key effector kinase in the cell cycle checkpoint response, checkpoint kinase 1 interacts with BTG3 to maintain genomic stability (Cheng et al. [@CR10]). BTG3 overexpression induces S/G2 arrest in gastric cancer cells (Gou et al. [@CR17]). Mao et al. ([@CR34]) reported that overexpression of BTG3 in CRC SW480 cells arrests the cell cycle at the G1 phase. In contrast, our studies show that downregulation of BTG3 in HCT16 and LoVo cells disturbed the cell cycle at the G2 phase. Different molecular phenotypes and epigenetic and genetic features may account for the different results. HCT116 cells are derived from Dukes' D stage primary tumor, SW480 cells are derived from Dukes' B stage primary tumor, and LoVo cells derived from Dukes' C stage are from supraclavicular metastasis sites (Ahmed et al. [@CR1]). Moreover, DNA methylation, point mutation, and microsatellite instability also differ in these cell lines (Ahmed et al. [@CR1]).

The formation of regional invasion and distant metastasis is the main cause of morbidity and mortality in patients with cancer. Previous studies have shown that upregulation of BTG3 suppresses the migration and invasion capabilities of gastric cancer (Gou et al. [@CR17]), and downregulation of BTG3 shows the opposite effect (Ren et al. [@CR39]). As mentioned above in our study, patients with CRC and lower BTG3 expression levels had an unfavorable prognosis after the operation. Thus, we hypothesized that BTG3 might also play a role suppressing migration and invasion of CRC cells. Our results show that a deficiency of BTG3 remarkably promoted CRC cell migration and invasive abilities of CRC cells in vitro.

A critical role of BTG3 in CRC development and progression has been demonstrated in patient samples and in human CRC cell lines. However, molecular mechanism studies about the biological functions of BTG3 in CRC remain elusive. Here, a genomic microarray analysis was conducted in the HCT116 CRC cell line with BTG3 knocked down and hundreds of genes were significantly differentially expressed. The IPA further detected the gene signatures with disease functions and identified multiple pathways involved in cancer development and progression. For instance, the ERK/MAPK signaling pathway, which was the top-enriched pathway following BTG3 knockdown. This pathway possesses multiple functions in cancer cells, such as cell viability, proliferation and cell cycle progression (Morgan et al. [@CR35]), apoptosis (Howie et al. [@CR21]; Alejandro and Johnson [@CR3]), differentiation (Dong et al. [@CR14]), angiogenesis (Zeng et al. [@CR54]; Huang et al. [@CR23]), and migration and invasion (Weng et al. [@CR46]; Lai et al. [@CR28]) (Fig. [3](#Fig3){ref-type="fig"}d). It is also closely associated with the occurrence, development, metastasis, and prognosis of tumors and is an important reference value for clinical diagnosis and treatment (Balmanno et al. [@CR4]; Zhang et al. [@CR55]). Signal transduction along this pathway begins with activation of the small GTPases Ras or Rap by receptor tyrosine kinases and G-protein-coupled receptors (Kolch [@CR27]). Next, the small G-proteins recruit c-Raf and B-Raf to the plasma membrane, where Raf is activated by binding to Ras (Kolch [@CR27]). Then, MEK-1/2 becomes activated by Raf and further phosphorylates ERK-1/2 at threonine and tyrosine residues (Yung et al. [@CR53]). Activated ERK regulates gene expression by directly phosphorylating transcription factors, such as Elk, and Myc, or indirectly by targeting substrates such as p90-RSK (ribosomal S6 kinase) family kinases (Davie and Spencer [@CR12]).

The IPA revealed that the expression of nine genes (RAP1A, PAK2, YWHAB, RPS6KA5, STAT3, DUSP6, STAT1, cFosm, and ATF4) involved in ERK/MAPK signaling was altered after BTG3 knockdown. The protein expression levels of the nine differentially expressed mRNAs were verified by western blotting analysis, and were mainly in accordance with the microarray data. Ras-related protein Rap-1A is a protein encoded by the RAP1A gene. Rap1 primarily regulates multiple integrin-dependent processes, such as morphogenesis, cell--cell adhesion, hematopoiesis, leukocyte migration, and tumor invasion (Bos et al. [@CR6]). Rap1 counteracts the mitogenic function of RAS because it competitively interacts with RAS GAPs and RAF (Han and Colicelli [@CR18]). PAK2 is one of three members of the Group I PAK family of serine/threonine kinases. PAK2 signaling modulates apoptosis (Bokoch [@CR5]) and cancers, including breast (Li et al. [@CR29]), hepatocarcinoma (Sato et al. [@CR41]), and gastric (Gao et al. [@CR16]). Pak2 may phosphorylate c-Raf, ultimately resulting in activation of ERK (Hough et al. [@CR20]). The YWHAB gene encodes the 14-3-3 protein, which is a beta/alpha protein in the 14-3-3 family of proteins. The 14-3-3 protein beta interacts with RAF1 and CDC25 phosphatases, suggesting that it may play a role linking mitogenic signaling and the cell cycle machinery (Qiu et al. [@CR38]). The 14-3-3 protein beta regulates proliferation of hepatocellular carcinoma cells, tumor growth, and chemosensitivity via the MAPK pathway (Wu et al. [@CR50]). MSK1 is a mitogen- and stress-activated protein kinase that is encoded by the RPS6KA5 gene and is activated by ERK and p38 MAPK in response to growth factors and cellular stress, respectively (Clark et al. [@CR11]). MSK1 mediates histone H3 phosphorylation and immediate-early gene expression and transmits external signals into various responses involved in cancer development (Healy et al. [@CR19]). Signal transducer and activator of transcription 3 (STAT3) is a transcription factor activated via phosphorylation of serine 727 by MAPK (Tkach et al. [@CR44]). STAT3 plays a key role in many cellular processes, such as cell growth and apoptosis (Yuan et al. [@CR52]). The protein dual specificity phosphatase 6 encoded by DUSP6 is a member of the dual specificity protein phosphatase subfamily (Muda et al. [@CR36]). As a negative regulator of ERK, DUSP6 suppresses tumorigenesis and EMT-associated phenotypes (Wong et al. [@CR49]). Contrary to STAT3 and STAT5, STAT1 is a tumor suppressor protein. Overexpression of STAT1 inhibits proliferation and migration but induces apoptosis in glioblastoma cells (Ju et al. [@CR25]). ATF4 has also been isolated and characterized as cAMP response element binding protein 2 (CREB-2). It is involved in regulating transcription in a wide variety of cell types (Karpinski et al. [@CR26]). Nerve growth factor, which activates a series of protein kinases via the ERK/MAPK signaling pathway, ultimately activates CREB (Sofroniew et al. [@CR43]). The target genes mediated by CREB play an important role in cell proliferation, differentiation, survival, and the cell cycle. CREB overexpression promotes cell survival and proliferation and results in the development of various tumors (Sakamoto and Frank [@CR40]). C-fos, referred to as an immediate early gene, is rapidly and transiently induced within 15 min of stimulation (Hu et al. [@CR22]). Its activity is regulated by post-translational modification by various kinases, such as MAPK (Hurd et al. [@CR24]). Our validation by western blotting indicated that PAK2, RPS6KA5, YWHAB, STAT3 were upregulated when BTG3 was depleted. In contrast, RAP1A, DUSP6, and STAT1 were downregulated in the BTG3/shRNA group compared with the NC group in HCT116 cells. This result might account for the phenotypes that downregulation of BTG3 expression could promote proliferation, inhibit apoptosis, and enhance invasion and metastasis of CRC cells. Interestingly, both cFos and ATF4 expressions did not change significantly. One possible reason may be that they are regulated by post-translational modification, such as phosphorylation. Nevertheless, our protein validation results implicate that the causal effect of BTG3 in CRC development and function may occur through regulation of the molecules mentioned above that are involved in ERK/MAPK signaling. The details of how BTG3 specifically interact with these molecules will be carried out in further studies.

In conclusion, our study confirmed the importance of BTG3 in CRC carcinogenesis and development and BTG3 might be considered a good biomarker for CRC prognosis. BTG3 knockdown in CRC cells promoted cell proliferation, migration, and invasion, disturbed the cell cycle, and impaired apoptosis by regulating multiple genes and cancer-associated pathways.
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